4.3 Article

Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with Type 1 diabetes mellitus

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influenza

Ashleigh R. Tuite et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)

Article Endocrinology & Metabolism

Diabetes and the Severity of Pandemic Influenza A (H1N1) Infection

Robert Allard et al.

DIABETES CARE (2010)

Letter Medicine, General & Internal

Responses to 2009 H1N1 Vaccine in Children 3 to 17 Years of Age

Adriano Arguedas et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Medicine, General & Internal

Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Article Medicine, General & Internal

A Novel Influenza A (H1N1) Vaccine in Various Age Groups.

Feng-Cai Zhu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Article Medicine, General & Internal

Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine.

Tristan W. Clark et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Article Medicine, General & Internal

Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team

Fatimah S. Dawood et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)